Zoetis Inc. (ZTS) Latest Filing Signal

Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, Zoetis Inc.'s filing signal continuing positive.

Zoetis Inc. is a global leader in the animal health industry, dedicated to the discovery, development, manufacture, and commercialization of a comprehensive range of medicines, vaccines, diagnostic products, and services. The company operates across eight core species, including companion animals like dogs, cats, and horses, and livestock such as cattle, swine, poultry, fish, and sheep. Its product portfolio spans seven major categories: parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceuticals, and animal health diagnostics. With a legacy of nearly 75 years, Zoetis aims to predict, prevent, detect, and treat animal illnesses, supporting veterinarians, pet owners, and livestock producers worldwide. The company's business is structured into two primary operating segments: the United States and International, with international operations accounting for 45% of its total revenue in 2025.

Zoetis' revenue is primarily driven by its diverse portfolio of animal health products, with companion animal products representing approximately 70% of its revenue in 2025, while livestock products accounted for approximately 29%. Key growth drivers include increasing pet owner spending, economic development, and advances in animal health treatments.